Health ❯ Healthcare ❯ Clinical Trials ❯ Phase 3 Trials

Eli Lilly Trials

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Full results will precede seven further Phase 3 readouts expected in 2026.

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings